Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YARON D LANGMAN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1568622678
CMS profile
162167
Location
POMONA, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,058.76

115 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YARON D LANGMAN

NPI 1568622678 · CMS profile ID 162167

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

POMONA, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568622678?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YARON D LANGMAN, NPI 1568622678, CMS profile ID 162167. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568622678?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). YARON D LANGMAN, NPI 1568622678, CMS profile ID 162167. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568622678?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
YARON D LANGMAN, NPI 1568622678, CMS profile ID 162167, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1568622678?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

115 matching records · $2,058.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 115 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 115.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Phathom Pharmaceuticals, Inc. $14.4607/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151086473 CMS
ABBVIE INC. $18.5007/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136882 CMS
GENZYME CORPORATION $5.4207/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139576295 CMS
Janssen Biotech, Inc. $17.8907/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078462973 CMS
Gilead Sciences, Inc. $21.4207/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133773811 CMS
Ardelyx, Inc. $20.4607/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146691254 CMS
ABBVIE INC. $25.0007/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136880 CMS
GENZYME CORPORATION $21.7006/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139576291 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.1406/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137613559 CMS
Janssen Biotech, Inc. $17.8906/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078463000 CMS
ABBVIE INC. $24.7506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136878 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.5206/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153623145 CMS
PFIZER INC. $14.8806/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131616514 CMS
ABBVIE INC. $19.7506/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136876 CMS
ABBVIE INC. $29.3906/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136872 CMS
ABBVIE INC. $4.9706/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136874 CMS
GENZYME CORPORATION $23.3205/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139576273 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.7905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153639902 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.8605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137613555 CMS
Gilead Sciences, Inc. $18.6405/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133773809 CMS
ABBVIE INC. $16.0005/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136870 CMS
Janssen Biotech, Inc. $15.9705/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078463008 CMS
Ferring Pharmaceuticals Inc. $19.1205/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137489490 CMS
ABBVIE INC. $5.4905/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136868 CMS
Merck Sharp & Dohme LLC $18.5305/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141595926 CMS
Regeneron Healthcare Solutions, Inc. $22.2705/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114095951 CMS
ABBVIE INC. $22.0405/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136866 CMS
ABBVIE INC. $2.6104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136864 CMS
Phathom Pharmaceuticals, Inc. $15.1404/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151086471 CMS
Janssen Biotech, Inc. $20.3204/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078463053 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.4104/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153462232 CMS
IRONWOOD PHARMACEUTICALS, INC $24.5204/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153755057 CMS
GENZYME CORPORATION $19.5604/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139576249 CMS
ABBVIE INC. $8.9104/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136860 CMS
ABBVIE INC. $0.6404/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136862 CMS
Takeda Pharmaceuticals U.S.A., Inc. $0.4304/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137613548 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.7604/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137613551 CMS
ABBVIE INC. $17.1704/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136858 CMS
Gilead Sciences, Inc. $15.3403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133773807 CMS
GENZYME CORPORATION $20.9503/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139576239 CMS
Lilly USA, LLC $20.1003/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135486846 CMS
Ferring Pharmaceuticals Inc. $16.8603/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137489485 CMS
Boston Scientific Corporation $16.4103/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092281242 CMS
Celgene Corporation $13.4003/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101151427 CMS
Janssen Biotech, Inc. $26.3103/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078463029 CMS
ABBVIE INC. $7.5603/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104136856 CMS
Regeneron Healthcare Solutions, Inc. $20.5503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114095949 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.4103/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137613544 CMS
Celgene Corporation $17.5302/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101151421 CMS
Phathom Pharmaceuticals, Inc. $17.3002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151086469 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $548.59 37
PY2020 $631.86 44
PY2021 $1,459.08 91
PY2022 $1,616.40 86
PY2023 $2,338.82 121
PY2024 $2,058.76 115
PY2025 $1,860.25 109

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Recipient $54.44 2
PY2020 Principal investigator $6,705.00 6
PY2019 Recipient $841.39 1
PY2019 Principal investigator $25,330.94 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

8 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $1,025.00 09/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721297139
Principal investigator 1 Allergan, Inc. $225.00 04/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721273339
Principal investigator 1 Allergan, Inc. $1,500.00 04/01/2020 Non-covered Recipient Entity
GEN1 RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721268397
Principal investigator 1 Allergan, Inc. $1,000.00 04/01/2020 Non-covered Recipient Entity
GEN1 RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721268409
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262459
Principal investigator 1 Eli Lilly and Company $2,000.00 03/09/2020 Non-covered Recipient Entity
GEN1 RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 728736377
Recipient Eli Lilly and Company $28.24 02/26/2020 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) No dispute reported 06/30/2026 728726291
Recipient Eli Lilly and Company $26.20 02/25/2020 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 728724145